Head-to-head evidence
HNC364 vs Safinamide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: MAO-B · full Parkinson's Disease pipeline
HNC364
Developed by Guangzhou Henovcom Bioscience Co. Ltd.
NCT05523570 · Phase 1 · completed
Participants were not randomized and neither they nor the investigators were blinded, and there was no placebo or comparator group, so this design cannot separate a real drug effect from chance, natural variation, or expectation. Results have not yet been posted.
Next expected readout: December 2026 · NCT06798519 (registry estimate)
Safinamide · Xadago
Marketed by Zambon SpA and partners
NCT00605683 · Phase 3 · completed
The study was randomized and double-blind, included 679 participants, and compared two safinamide doses with placebo. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2027 · NCT07761936 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HNC364's landscape · Safinamide's landscape